Drugs / Flu-M Quadro
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05152017 | Nov 2019 → Jan 2020 | influenza | St. Petersburg Research Institute of Vaccines and Sera | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT05869201 Comparator | Oct → Dec 2020 | influenza | St. Petersburg Research Institute of Vaccines and Sera | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Flu-M Quadro | “The goal of this clinical trial is to assess tolerability, safety and immunogenicity of the Flu-M Quadro vaccine as compared to the Ultrix® Quadri vaccine in volunteers aged...” NCT05869201 ↗ |
| Modality | Vaccine | “inactivated split influenza vaccine” NCT05152017 ↗ |
| Route | Intramuscular | “solution for intramuscular injection, 0.5 ml” NCT05152017 ↗ |